Kim, H. Y. ¶, Mizrahi, O. ¶, Lee, W., Rosenthal, S. B., . . . Kisseleva, T., Yeo, G. W., and Brenner, D. A. (2026) RNA-binding protein LARP6 coordinates hepatic stellate cell activation and liver fibrosis.  The Journal of Clinical Investigation, 136, 8, IF=13.6

Lee, S.M., Hwang, D.K., and Kim, H.Y. (2026) New approach methodologies to model liver fibrosis in metabolic dysfunction-associated steatohepatitis. BMB Reports 59, 219-226, IF=3.3

Park, J., Lee, M.H., Kim, H.Y., Kim, H.S., Kim, S.K., Yang, J.W., and Kang, K.W. (2026) A Novel Anti-Fibrotic Role of G-Protein-Coupled Receptor 119 in Hepatic Stellate Cells. Biomolecules & Therapeutics, 34, 666-675, IF=3.2

Sakane, S., Nishio, T., Fuji, H., Park, S.Y., Ishizuka, K., Miciano, C., Kimura, Y., Hosseini, M., Diggle, K., Zhang, V., Kim, H.Y. . . . et al. (2026) Mesothelin/Mucin 16 Signaling in Activated Portal Fibroblasts Drives the Development of Cholestatic Fibrosis and Hepatocellular Carcinoma in Aged Female Multidrug Resistance Protein 2 Knockout Mice. Cellular and Molecular Gastroenterology and Hepatology, 101785, IF=7.4

Lee, Y.J., Choi, H.-I., Hwang, J.-h., Park, M., Choi, M., Kim, H.Y., Kim, Y.S., Nam, K.T., Kim, J.-K., Lim, K.-M., and Kang, K.W. (2026) Phosphatidylserine-Rich circulating extracellular vesicles activate TAM receptor signaling to promote skin wound repair. Biochemical Pharmacology, 249, 117941, IF=5.6

Lee. W.¶, Liu. X.¶, Rosenthal. S.B., Miciano C., Chakraborty S., Dhar D., Kim, H. Y, Brenner D.A., Kisseleva T. (2025) Deletion of ETS1 in hepatic stellate cells accelerates development of liver fibrosis. JCI Insight, 10(24), IF=6.1

Kim, H. Y. ¶, Rosenthal, S. B. ¶, Liu, X. ¶, . . . Wang, A., Brenner, D. A., Kisseleva, T. (2025) Multi-Modal Analysis of human Hepatic Stellate Cells identifies novel therapeutic targets for Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Hepatology, 82(5), 882-897, IF=33.0

Felipe, C.G.D.R, Theresa, V.R, .. . .. Kim, H. Y., Kisseleva, T., Ying, W., and Olefsky, J. M. (2025), MASH adipose tissue macrophages secrete extracellular vesicles that activate liver fibrosis in obese male mice. Gastroenterology, 169(4), 691-704, IF=25.1

Yamamoto, G. ¶, Weber, R. C-G. ¶, .. . .. Kim, H. Y., Brenner, D. A., Li, N., Kisseleva, T. (2025) DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids. JHep Report, 101415, IF=7.5

Yoo, S.-Y. ¶, Kim, H. Y. ¶, Kim, D. H., Shim, W. S., Lee, S. M., Lee, D. H., Koo, J. M., Yoo, J. H., Koh, S., Park, J. C., Yu, J., Jeon, J. S., Baek, M.-J., Kim, D.-D., Lee, J.-Y., Oh, S. J., Kim, S. K., Lee, J.-Y., & Kang, K. W. (2024). Laser-responsive erastin-loaded chondroitin sulfate nanomedicine targeting CD44 and system xc− in liver cancer: A non-ferroptotic approach. Journal of Controlled Release, 375, 574-588, IF=11.5

Kim, H. Y. ¶, Lee, W. ¶, Liu, X., Jang, H., Sakane, S., Carvalho-Gontijo Weber, R., Diggle, K., Kerk, S. A., Metallo, C. M., Kisseleva, T., & Brenner, D. A. (2024). Protocol to generate human liver spheroids to study liver fibrosis induced by metabolic stress. STAR Protocols, 5(2), 103111.

Osna, N. A., Tikhanovich, I., Ortega-Ribera, M., Mueller, S., Zheng, C., Mueller, J., Li, S., Sakane, S., Weber, R. C. G., Kim, H. Y., Lee, W., Ganguly, S., Kimura, Y., Liu, X., Dhar, D., Diggle, K., Brenner, D. A., Kisseleva, T., Attal, N., . . . Kharbanda, K. K. (2024). Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression. Biomolecules, 14(4), 404, IF=4.8

Kim, H. Y., Sakane, S., Eguileor, A., Carvalho Gontijo Weber, R., Lee, W., Liu, X., Lam, K., Ishizuka, K., Rosenthal, S. B., Diggle, K., Brenner, D. A., & Kisseleva, T. (2024). The Origin and Fate of Liver Myofibroblasts. Cellular and Molecular Gastroenterology and Hepatology, 17(1), 93-106, IF=7.4

An, Y. J., Jo, S., Kim, J.-M., Kim, H. S., Kim, H. Y., Jeon, S.-M., Han, D., Yook, J. I., Kang, K. W., & Park, S. (2023). Lactate as a major epigenetic carbon source for histone acetylation via nuclear LDH metabolism. Experimental & Molecular Medicine, 55(10), 2238-2247, IF=12.9

Kim, H. Y., Otgontenger, U., Kim, J. W., Lee, Y. J., Kim, S. B., Lim, S. C., Kim, Y. M., & Kang, K. W. (2023). Anti-fibrotic effect of aurocyanide, the active metabolite of auranofin. Archives of Pharmacal Research, 46(3), 149-159, IF=7.5

Liu, X., Lam, K., Zhao, H., Sakane, S., Kim, H. Y., Eguileor, A., Diggle, K., Wu, S., Weber, R.C. G, Soroosh, P., Hosseini, M., Mekeel, K., Brenner, D. A., & Kisseleva, T. (2023). Isolation of primary human liver cells from normal and nonalcoholic steatohepatisic (NASH) livers. STAR protocols, 4 (3), 102391

Cabré, N., Hartmann, P., Llorente, C., Kouno, T., Wang, Y., Zeng, S., Kim, H. Y., Zhang, X., Kisseleva, T., Iyer, S., Kudumala, S., & Schnabl, B. (2023). IgY antibodies against cytolysin reduce ethanol-induced liver disease in mice. Hepatology, 78(1), 295-306, IF=15.8

Lee, Y. J., Park, M., Kim, H. Y., Kim, J.-K., Kim, W.-K., Lim, S. C., & Kang, K. W. (2023). Circulating small extracellular vesicles promote proliferation and migration of vascular smooth muscle cells via AXL and MerTK activation. Acta Pharmacologica Sinica, 44(5), 984-998, IF=8.4

Lee, W., Kim, H. Y., Choi, Y. J., Jung, S. H., Nam, Y. A., Zhang, Y., Yun, S. H., Chang, T. S., & Lee, B. H. (2022). SNX10-mediated degradation of LAMP2A by NSAIDs inhibits chaperone-mediated autophagy and induces hepatic lipid accumulation. Theranostics, 12(5), 2351-2369, IF=13.3 

Kim, H. Y., G. H. Baek, W. Lee, Y. J. Lee, W. Shim, Y. J. Choi, B.-H. Lee, S. K. Kim¶, and K. W. Kang¶ (2022) CD44 is involved in liver regeneration through enhanced uptake of extracellular cystine. Clinical and Translational Medicine. 12(5):e873, IF=6.8

Kim, H. Y., Choi, Y. J., Kim, S. K., Kim, H., Jun, D. W., Yoon, K., Kim, N., Hwang, J., Kim, Y.-M., Lim, S. C., & Kang, K. W. (2021). Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome. Communications Biology, 4(1), 824, IF=5.1

Yoo, T., Joo, S. K., Kim, H. J., Kim, H. Y., Sim, H., Lee, J., Kim, H.-H., Jung, S., Lee, Y., Jamialahmadi, O., Romeo, S., Jeong, W.-I., Hwang, G.-S., Kang, K. W., Kim, J. W., Kim, W., & Choi, M. (2021). Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. Journal of Hepatology, 75(3), 514-523, IF=33.0

An, S., Kim, G., Kim, H. J., Ahn, S., Kim, H. Y., Ko, H., Hyun, Y. E., Nguyen, M., Jeong, J., Liu, Z., Han, J., Choi, H., Yu, J., Kim, J. W., Lee, H. W., Jacobson, K. A., Cho, W. J., Kim, Y.-M., Kang, K. W., . . . Jeong, L. S. (2020). Discovery and Structure–Activity Relationships of Novel Template, Truncated 1′-Homologated Adenosine Derivatives as Pure Dual PPARγ/δ Modulators. Journal of Medicinal Chemistry, 63(24), 16012-16027, IF=6.8

Sim, W.-C., Lee, W., Sim, H., Lee, K.-Y., Jung, S.-H., Choi, Y.-J., Kim, H. Y., Kang, K. W., Lee, J.-Y., Choi, Y. J., Kim, S. K., Jun, D. W., Kim, W., & Lee, B.-H. (2020). Downregulation of PHGDH expression and hepatic serine level contribute to the development of fatty liver disease. Metabolism-Clinical and Experimental, 102, 154000, IF=11.9

Kim, H. Y., Kim, K. S., Kim, M. J., Kim, H.-S., Lee, K.-Y., & Kang, K. W. (2019). Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing Inhibitors of κB Kinase and Inflammasome-Mediated Interleukin-1β Secretion. Oxidative Medicine and Cellular Longevity, 3503912, IF=7.3

On, S.¶, Kim, H. Y. ¶, Kim, H. S., Park, J., & Kang, K. W. (2019). Involvement of G-Protein-Coupled Receptor 40 in the Inhibitory Effects of Docosahexaenoic Acid on SREBP1-Mediated Lipogenic Enzyme Expression in Primary Hepatocytes. International Journal of Molecular Sciences, 20(11), 2625, IF=4.9